METHOTREXATE INJECTION, USP SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

METHOTREXATE (METHOTREXATE SODIUM)

Доступна с:

STRIDES PHARMA CANADA INC

код АТС:

L01BA01

ИНН (Международная Имя):

METHOTREXATE

дозировка:

25MG

Фармацевтическая форма:

SOLUTION

состав:

METHOTREXATE (METHOTREXATE SODIUM) 25MG

Администрация маршрут:

INTRA-ARTERIAL

Штук в упаковке:

2ML/40ML

Тип рецепта:

Prescription

Терапевтические области:

ANTINEOPLASTIC AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0107545002; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2013-12-03

Характеристики продукта

PAGE 1 OF 47
PRODUCT MONOGRAPH
PR
METHOTREXATE INJECTION, USP
Unpreserved
25 mg/mL methotrexate (as methotrexate sodium)
Sterile Solution
Intramuscular, intravenous, intra-arterial, intrathecal, and
intracerebroventricular
ANTIMETABOLITE AND ANTIRHEUMATIC
Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet
Varennes, Quebec
J3X 1P7
Date of Revision:
October 14, 2021
Submission Control No.: 254503
PAGE 2 OF 47
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
13
DRUG INTERACTIONS
.........................................................................................................
16
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
........................................................................................................................
29
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
29
STORAGE AND STABILITY
.................................................................................................
32
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 33
PART II: SCIENTIFIC INFORMATION
........................................................................